<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7D9B4D62-B1BB-4DEC-9664-795B9EC472D7"><gtr:id>7D9B4D62-B1BB-4DEC-9664-795B9EC472D7</gtr:id><gtr:name>School of Medicine Alabama at Birmingham</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Genetics and Molecular Medicine</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7D9B4D62-B1BB-4DEC-9664-795B9EC472D7"><gtr:id>7D9B4D62-B1BB-4DEC-9664-795B9EC472D7</gtr:id><gtr:name>School of Medicine Alabama at Birmingham</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3611393C-B14F-4035-B03B-9F07C2EAAD6F"><gtr:id>3611393C-B14F-4035-B03B-9F07C2EAAD6F</gtr:id><gtr:firstName>Gillian</gtr:firstName><gtr:surname>Bates</gtr:surname><gtr:orcidId>0000-0002-4041-6305</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/12C54480-A4EB-44AC-997B-B44CF4F2F020"><gtr:id>12C54480-A4EB-44AC-997B-B44CF4F2F020</gtr:id><gtr:firstName>Michel</gtr:firstName><gtr:surname>Modo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7ADD968D-1D63-4687-B530-A7EC95C89DDF"><gtr:id>7ADD968D-1D63-4687-B530-A7EC95C89DDF</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:otherNames>Joanna</gtr:otherNames><gtr:surname>Tabrizi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0800846"><gtr:id>50F3E232-0611-44FE-B136-2452CA684874</gtr:id><gtr:title>Identification and Cross-validation of Early Stage Phenotypes in Mouse Models of Huntington s disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800846</gtr:grantReference><gtr:abstractText>Huntington?s disease (HD) is an inherited neurodegenerative disorder with an average age of onset of 40 years. Affected individuals lose their ability to control movement, develop psychiatric problems, an impaired mental capacity and lose weight. The disease progresses for 15-20 years until patients have almost no movement and cannot swallow or speak. There are effective treatments for some psychiatric problems (e.g. depression) but there is no way to halt or slow the mental decline or disease progression. The European Huntington?s Disease Network (EHDN) (funded by the CHDI Foundation) has been established to provide the infrastructure, tools and resources necessary to perform clinical trials for HD in Europe. Unlike Alzheimer?s and Parkinson?s disease, HD is always inherited and a genetic test can be used to diagnose individuals with early stage disease and before symptoms develop. This group of people will be particularly suited to receive disease-modifying treatments once they are developed. To develop the tests to monitor the emergence and progression of disease in this group, the CHDI Foundation has funded TRACK-HD, a three year initiative that commenced in 2007 to develop clinical, magnetic resonance imaging and blood tests and compare their utility. 
The mechanisms that underlie HD are extremely complex and many potential therapeutic avenues have been proposed. However, because clinical trials will remain resource intensive and expensive, the number of drugs that can be tested in the clinic will inevitably be limited. Mice that have been genetically altered to carry the HD mutation are very good models of the human disease. Therefore, because drug trials can be performed relatively quickly in mice, the demonstration that a treatment has a beneficial effect in an HD mouse model is the factor most likely to be used to prioritise drugs for testing in clinical trials. Therefore, mouse trials must be rigorous, controlled and reproducible and ideally incorporate tests that are relevant to the human disease. In partnership with the CHDI Foundation, we shall conduct a detailed comparative evaluation of HD mouse models, with a particular focus on presymptomatic and early stage disease using tests chosen to complement the TRACK-HD clinical study. This project will inform the design of mouse trials using tests that emerge as being the most useful for clinical evaluation. This synergy will maximise the chance of translating successful therapeutic strategies for HD into the clinic using validated HD mouse models.</gtr:abstractText><gtr:technicalSummary>Huntington?s disease (HD) is an autosomal dominant neurodegenerative disorder with a mean age of onset of 40 years. Symptoms include motor disorders, psychiatric disturbances, cognitive decline and weight loss, disease duration is approximately 15-20 years and death occurs from co-morbid events. Effective symptomatic therapy is available for some psychiatric symptoms, but treatment of the motor disorder is challenging and there are no therapies that halt or slow the cognitive decline or disease progression. The combination of a slowly progressive disease of variable presentation with a poor battery of assessment tools has meant that phase III clinical efficacy trials performed to date have been underpowered. To remedy this situation, the European Huntington?s Disease Network (EHDN) (funded by the CHDI Foundation) has been established to provide the infrastructure, tools and resources necessary to perform clinical trials for HD in Europe. Because HD is an autosomal dominant disease with a genetic diagnostic test, virtually all individuals in the ultimate HD target group, those with premanifest or early stage disease, can be determined with certainly. To develop the assessment tools to monitor the emergence and progression of disease in this group, the CHDI Foundation has funded TRACK-HD, a three year initiative that commenced in 2007 to identify and compare head-to-head clinical, imaging and wet biomarker assessment tools. 
The molecular pathogenesis of HD is extremely complex and many potential therapeutic targets have been proposed. However, because clinical efficacy trials will remain resource intensive and expensive, the number of compounds that can be tested in the clinic will inevitably be limited. The demonstration that a therapeutic strategy has disease modifying effects when administered to HD mouse models is the factor most likely to influence the prioritisation of compounds entering the clinical. Therefore, preclinical efficacy trials must be as rigorous, controlled and reproducible as possible and ideally will incorporate clinically cross-validated outcome measures. In partnership with the CHDI Foundation, this proposal will conduct a detailed comparative evaluation of HD mouse models, with a particular focus on presymptomatic and early stage disease using outcome measures chosen to complement the TRACK-HD clinical study. It aims to inform the design of preclinical assessment trials and to match the choice of outcome measures to those that will emerge as being the most useful for clinical evaluation. This synergy will maximise the chance of translating successful therapeutic strategies for HD into the clinic using validated HD mouse models.</gtr:technicalSummary><gtr:fund><gtr:end>2012-12-13</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>682744</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine Alabama at Birmingham</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Biochemistry and Molecular Genetics</gtr:department><gtr:description>HD KI models</gtr:description><gtr:id>23F449B3-C740-49F5-B635-B6775F5E149A</gtr:id><gtr:impact>Sathasivam K*, Neueder A*, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RLM, Roos RAC, Howland D, Detloff PJ, Housman DE, Bates GP (2013). Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington's disease. Proc. Natl. Acad. Sci. 110, 2366-2370.</gtr:impact><gtr:partnerContribution>provided mouse models</gtr:partnerContribution><gtr:piContribution>analysed mouse models in the publication below</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>cardiac MRI for mice</gtr:description><gtr:id>F80F0752-259E-4423-AF92-1D020449AF1C</gtr:id><gtr:impact>Mielcarek et al PLoS Genetics 10, e1004550 2014</gtr:impact><gtr:partnerContribution>Advice on and supervision for cardiac MRI analysis</gtr:partnerContribution><gtr:piContribution>Provided the mouse models of HD for scanning as part of a much wider analysis of cardiac dysfunction</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>tensor based morphometry of MRI</gtr:description><gtr:id>CB0D03F7-E03B-4256-B95B-01D012C2336F</gtr:id><gtr:impact>Rattray et al 2013 PLoS ONE 8: e84726
Rattray et al 2017 PLoS ONE 12: e0168556</gtr:impact><gtr:partnerContribution>Applied tensor based morphometric analysis that they had developed</gtr:partnerContribution><gtr:piContribution>Provided longitudinal in vivo and ex vivo MRI scans of a mouse model of HD</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Headmasters annual conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>35B94A10-2214-4D0D-A69B-3A4613161EB5</gtr:id><gtr:impact>Headmasters experienced going back to school for a day. Gave a lesson to approx. 30 headmasters

good feedback and request for transcript of presentation</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Brompton Oratory)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B4CFE68C-7312-4BFB-92FF-8ECB7B6F5E73</gtr:id><gtr:impact>talk to and discussion with 6th formers about the ethics and implications of genetic research

Very positive feedback, the school regretted not having made a video of the afternoon</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>symposium at care home</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0C4EAE50-5DE7-4CFF-BDB7-85692133F10E</gtr:id><gtr:impact>talk given to ~ 80 GPs, carers, physiotherapists etc involved in the care of HD patients.

Request to visit the research lab</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Careers afternoon for graduate students</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>28C9FD7A-1C79-497D-9246-4B1D0E234CAB</gtr:id><gtr:impact>Facilitated a careers afternoon for postgraduate students funded by the Neuromodel EU Marie Curie training netwrok

Good feedback from the students about the presentations and the opportunity to discuss career options</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK HD netwrok</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>53D39AD5-7AD6-4230-B760-09DF100B274B</gtr:id><gtr:impact>Approximately 100 health professional involved in the care of Huntinton's disease (physiotherapists, psychologists, social workers etc.) and lay group members

Have been asked to address a psychiatric conference</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>125370</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>grant support</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>CHDI Foundation</gtr:fundingOrg><gtr:id>433871B3-FC50-40D1-96D5-6112436E4611</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EU JPND research initiative</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>2A5C0160-2F6A-4C75-83FA-59BA2FAC8978</gtr:id><gtr:impact>The Joint Programming Initiative in Neurodegeneration (JPND) has been established by 23 European countries to address the growing societal challenge presented by age-related neurodegeneration. This initiative spans the biomedical, healthcare and social science agendas, and seeks to improve the scientific understanding of neurodegenerative disorders, provide new approaches for their prevention, diagnosis and treatment, and ensure effective provision of health and social care and support, so that individuals can receive optimum care at all stages of their illness.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/382E601A-EFAD-49E1-8B01-58C6319BAEFB"><gtr:id>382E601A-EFAD-49E1-8B01-58C6319BAEFB</gtr:id><gtr:title>Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/98f854e4347f651aa6b98a4f1b9632eb"><gtr:id>98f854e4347f651aa6b98a4f1b9632eb</gtr:id><gtr:otherNames>Rattray I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/060267B7-BE72-4F7D-BC55-B2A43B32F622"><gtr:id>060267B7-BE72-4F7D-BC55-B2A43B32F622</gtr:id><gtr:title>Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease.</gtr:title><gtr:parentPublicationTitle>BMC neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/430ec4d954d273e09aa2c65dbfa2c4f2"><gtr:id>430ec4d954d273e09aa2c65dbfa2c4f2</gtr:id><gtr:otherNames>El-Akabawy G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-2202</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E3BE311D-BAA6-4308-8D04-F469C954FF68"><gtr:id>E3BE311D-BAA6-4308-8D04-F469C954FF68</gtr:id><gtr:title>Implantation site and lesion topology determine efficacy of a human neural stem cell line in a rat model of chronic stroke.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/60a25835a2b5de16921804d374f9d906"><gtr:id>60a25835a2b5de16921804d374f9d906</gtr:id><gtr:otherNames>Smith EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/092CDD2E-7ED1-409A-B1B3-5430FE948FD7"><gtr:id>092CDD2E-7ED1-409A-B1B3-5430FE948FD7</gtr:id><gtr:title>Dysfunction of the CNS-heart axis in mouse models of Huntington's disease.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eb9c5d48c8dcf4897e3817b8dc39687d"><gtr:id>eb9c5d48c8dcf4897e3817b8dc39687d</gtr:id><gtr:otherNames>Mielcarek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/93C9BE46-FBAA-4404-82A0-C36634403F9E"><gtr:id>93C9BE46-FBAA-4404-82A0-C36634403F9E</gtr:id><gtr:title>MR diffusion histology and micro-tractography reveal mesoscale features of the human cerebellum.</gtr:title><gtr:parentPublicationTitle>Cerebellum (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/21f7275789151c097ea6ddc9d799444f"><gtr:id>21f7275789151c097ea6ddc9d799444f</gtr:id><gtr:otherNames>Dell'Acqua F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-4222</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A610A8BD-4F0F-4AE3-90ED-C46A9DA819CB"><gtr:id>A610A8BD-4F0F-4AE3-90ED-C46A9DA819CB</gtr:id><gtr:title>Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/98f854e4347f651aa6b98a4f1b9632eb"><gtr:id>98f854e4347f651aa6b98a4f1b9632eb</gtr:id><gtr:otherNames>Rattray I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4DAFB396-17B1-4F0C-9CFA-9743FF1B2E6F"><gtr:id>4DAFB396-17B1-4F0C-9CFA-9743FF1B2E6F</gtr:id><gtr:title>Advances in the application of MRI to amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Expert opinion on medical diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea741f74cf7c60cbe6521035c8abbc4c"><gtr:id>ea741f74cf7c60cbe6521035c8abbc4c</gtr:id><gtr:otherNames>Turner MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1753-0059</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6DFC0995-597C-4F6D-8ACD-36F2CC51685F"><gtr:id>6DFC0995-597C-4F6D-8ACD-36F2CC51685F</gtr:id><gtr:title>Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the HdhQ150/Q150 Mouse Model of Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/98f854e4347f651aa6b98a4f1b9632eb"><gtr:id>98f854e4347f651aa6b98a4f1b9632eb</gtr:id><gtr:otherNames>Rattray I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800846</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>